Author: Thiru

On Friday, 18 November 2011, the WHO Consultative Expert Working Group on research and development: financing and coordination (CEWG) held an open briefing on the results of its work thus far. This meeting was attended by delegates from Bangladesh, Brazil, the European Union, Germany, the Holy See, the Netherlands, Nigeria, Tanzania, United States in addition to representatives from the Global Fund, South Centre, WHO, WIPO, UNITAID, Berne Declaration, HAI, KEI, IFPMA, MPP, MSF and TWN.

Continue Reading →

In May 2010, the World Health Organization (WHO) passed resolution WHA63.23 which established the Consultative Expert Working Group on research and development: financing and coordination (CEWG) to further “examine current financing and coordination of research and development, as well as proposals for new and innovative sources of funding to stimulate research and development related to Type II and Type III diseases and the specific research and development needs of developing countries in relation to Type I diseases, and open to consideration of proposals from Member States”. Continue Reading →

The following is the intervention delivered by Brazil on 1 November 2011 at the Special Session of the Executive Board on WHO Reform.

INTERVENCÃO DA EMBAIXADORA MARIA NAZARETH FARANI AZEVÊDO NA ABERTURA DA SESSÃO
ESPECIAL DO CONSELHO EXECUTIVO DA OMS SOBRE A REFORMA DA ORGANIZACÃO

Genebra, 1º de novembro de 2011

Mr. Chairman,

Continue Reading →

On 25 October 2011, the WTO TRIPS Council held its annual review of the Paragraph 6 System under Item G. Under the sub-heading of alternatives to the Paragraph 6 system, Ecuador asked the European Union (EU) about the issuance of three compulsory licenses in Italy between 2005 to 2007. In its intervention, Ecuador asked the EU for more detail regarding the Italian Competition Authority’s issuance of compulsory licenses for export to Spain and other EU members in cases involving Glaxo and Merck including, but not limited to, administrative procedures, decision-making processes, and rationale. Continue Reading →

This is the intervention that the United States made on ACTA on 25 October 2011 during the WTO TRIPS Council discussions of “Enforcement of Intellectual Property Rights”.

O. ENFORCEMENT OF INTELLECTUAL PROPERTY RIGHTS (PARTY III OF THE TRIPS AGREEMENT)

The United States thanks Japan for its opening remarks, with which we fully associate ourselves.

We appreciate this opportunity to share with colleagues from other WTO Members our views on the importance of enforcement and to provide some additional information on the ACTA.

Continue Reading →

G. REVIEW UNDER PARAGRAPH 8 OF THE DECISION ON THE IMPLEMENTATION OF PARAGRAPH 6 OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND PUBLIC HEALTH

We welcome the opportunity to participate in the annual review on the implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health.

Continue Reading →

OCTOBER TRIPS COUNCIL MEETING
October 24-25, 2011
Canada’s Intervention for Agenda Item G (Access to Medicines)

Mr. Chairman, Canada welcomes this opportunity to discuss the implementation of the Paragraph 6 system and to share some thoughts on the issue of access to medicines.

Continue Reading →

On Tuesday, 25 October 2011, Canada made the following intervention at the WTO TRIPS Council on ACTA under agenda item O, “Trends in Enforcement”.

In relation to the WTO Doha Declaration on the TRIPS Agreement and Public Health, Canada asserted the following,

ACTA is also consistent with the TRIPS Agreement and the Declaration on TRIPS and Public Health and will not hinder the cross-border transit of legitimate generic medicines.

OCTOBER TRIPS COUNCIL MEETING
October 24-25, 2011
Continue Reading →

On 25 October 2011, India delivered the following intervention at the WTO TRIPS Council raising concerns on ACTA and the TPPA during discussions of “Trends in the Enforcement of Intellectual Property Rights”. On ACTA, India voiced concerns on the scope of ACTA’s civil enforcement measures, border measures potential role in the seizure of generic medicines, third party liability, damages and also raised systemic issues such as how WTO MFN obligations would affect WTO members who are not ACTA parties,

Continue Reading →

On 25 October 2011, the WTO TRIPS Council held its annual review of the Paragraph 6 System. The following are extracts from the intervention of India. Note that under “Any alternatives to the use of Paragraph 6 System to achieve the objective of access to medicines” India asked the United States to shed light on state practice in the US following the US Supreme Court’s eBay versus MercExchange ruling (/content/view/174/1). Continue Reading →